Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Other financing activities (2016 - 2018)

Historic Other financing activities for Vanda Pharmaceuticals (VNDA) over the last 8 years, with Q1 2018 value amounting to $2.7 million.

  • Vanda Pharmaceuticals' Other financing activities rose 2068.81% to $2.7 million in Q1 2018 from the same period last year, while for Mar 2018 it was $5.7 million, marking a year-over-year decrease of 4255.23%. This contributed to the annual value of $5.3 million for FY2017, which is 3225.39% down from last year.
  • As of Q1 2018, Vanda Pharmaceuticals' Other financing activities stood at $2.7 million, which was up 2068.81% from $81000.0 recorded in Q4 2017.
  • Over the past 5 years, Vanda Pharmaceuticals' Other financing activities peaked at $5.9 million during Q3 2016, and registered a low of $24000.0 during Q1 2016.
  • For the 5-year period, Vanda Pharmaceuticals' Other financing activities averaged around $1.4 million, with its median value being $759000.0 (2016).
  • Within the past 5 years, the most significant YoY rise in Vanda Pharmaceuticals' Other financing activities was 12230000.0% (2014), while the steepest drop was 9597.48% (2014).
  • Over the past 5 years, Vanda Pharmaceuticals' Other financing activities (Quarter) stood at $174000.0 in 2014, then skyrocketed by 1956.9% to $3.6 million in 2015, then tumbled by 79.04% to $750000.0 in 2016, then crashed by 89.2% to $81000.0 in 2017, then soared by 3191.36% to $2.7 million in 2018.
  • Its Other financing activities stands at $2.7 million for Q1 2018, versus $81000.0 for Q4 2017 and $768000.0 for Q3 2017.